Abstract:BACKGROUND:Combretastatin A-4 (CA-4) is a natural product isolated from the bark of the South African bush willow tree Combretum caffrum, which exerts tubulin inhibition, but its clinical application is limited due to poor stability and water solubility. 2-aryl benzimidazoles are excellent pharmacological skeletons with many activities, especially in tumor inhibition, and better pharmacokinetic properties. Several scaffold CA-4 analogs have been synthesized to date possessing antitumor activities.OBJECTIVE:The benzimidazole was applied as the core moiety to replace the B ring and unstable linkage of CA-4, and the 5-aryl acetenyl group was introduced to improve the antitumor activity. MCF-7, A549, Caco-2, Siha, and Eca-109 tumor cell lines were used to study inhibition by these agents in vitro.METHODS:The benzimidazole structure was constructed from the oxidation of o-nitroaniline and aldehyde and the following schemes, and the structural characterization was carried out. The antitumor effects were evaluated in vitro through MTT assay, cell cycle arrest, and apoptosis assay. Molecular docking with tubulin (Protein ID: 1SA0) was analyzed for the structure-activity relationship.RESULTS:Among these derivatives, 4a-4h series (with 6-methoxy group) compounds inhibited the tumor cell lines much stronger than the CA-4 and cisplatin, especially compound 4f showed prominently inhibitory activity in Siha cell with IC50 value as 0.61 μmol/L. The further assay showed that the cell cycle was arrested at the G0/G1 phase as well verified in apoptosis assay. Molecular docking indicated that 4f had stronger affinity energy and hydrogen bond than CA-4.CONCLUSION:The compound 4f has the potency to be used as an anti-tubulin agent and the 2-trimethoxyphenyl benzimidazole skeleton deserves further study as an antitumor structure.

Novel Combretastatin A-4 Derivative Containing Aminophosphonates As Dual Inhibitors of Tubulin and Matrix Metalloproteinases for Lung Cancer Treatment.

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Novel Combretastatin A-4 Derivative XN0502 Induces Cell Cycle Arrest and Apoptosis in A549 Cells.

Design, concise synthesis and evaluation of novel amide-based combretastatin A-4 analogues as potent tubulin inhibitors

Synthesis and mechanistic studies of novel spin-labeled combretastatin derivatives as potential antineoplastic agents.

Design and Synthesis of Cyclopropylamide Analogues of Combretastatin-A4 As Novel Microtubule-Stabilizing Agents

Synthesis, biological evaluation and mechanism study of a class of cyclic combretastatin A-4 analogues as novel antitumour agents

Synthesis, Mechanisms of Action, and Toxicity of Novel Aminophosphonates Derivatives Conjugated Irinotecan in Vitro and in Vivo As Potent Antitumor Agents.

Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents

Design, Synthesis, Biological Evaluation and Cocrystal Structures with Tubulin of Chiral Β-Lactam Bridged Combretastatin A-4 Analogues As Potent Antitumor Agents.

Identification of Novel 1-Indolyl Acetate-5-nitroimidazole Derivatives of Combretastatin A-4 As Potential Tubulin Polymerization Inhibitors.

A Novel Synthetic Compound Exerts Effective Anti-Tumour Activity in Vivo Via the Inhibition of Tubulin Polymerisation in A549 Cells.

Design, Synthesis, and Biological Evaluation of Novel Benzodiazepine Derivatives As Anticancer Agents Through Inhibition of Tubulin Polymerization in Vitro and in Vivo

Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action.

Anti-tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models.

A Novel Tubulin Inhibitor, 6h, Suppresses Tumor-Associated Angiogenesis and Shows Potent Antitumor Activity Against Non–small Cell Lung Cancers

Design, Synthesis, and Anti-tumor Activity of Novel 2-Aryl Benzimidazole Compounds.

A Class of Novel Tubulin Polymerization Inhibitors Exert Effective Anti-Tumor Activity Via Mitotic Catastrophe.

Discovery of Novel 4-Arylisochromenes As Anticancer Agents Inhibiting Tubulin Polymerization.

Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo

A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells.